O2-Vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate Protection Againstd-Galactosamine/Endotoxin-Induced Hepatotoxicity in Mice: Genomic Analysis Using Microarrays
- Jie Liu1,
- Joseph E. Saavedra4,
- Tong Lu1,
- Jian-Guo Song3,
- James Clark2,
- Michael P. Waalkes1 and
- Larry K. Keefer5
- 1Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at National Institute of Environmental Health Sciences, (J.L., T.L., M.P.W.) and 2Comparative Medicine Branch (J.C.), National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina; 3Academica Sinica Biochemistry Institute, Shanghai, China (J.-G.S.); 4Science Applications International Corporation-Frederick (J.E.S.) and 5Chemistry Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick (L.K.K.), Frederick, Maryland
- Dr. Jie Liu, Inorganic Carcinogenesis Section, National Cancer Institute at National Institute of Environmental Health Sciences, Mail Drop F0–09, Research Triangle Park, NC 27709. E-mail: Liu6{at}niehs.nih.gov
Abstract
O2-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), a liver-selective nitric oxide (NO)-donating prodrug, is metabolized by hepatic enzymes to release NO within the liver. This study was undertaken to examine the effects of V-PYRRO/NO ond-galactosamine/lipopolysaccharide (GlaN/LPS)-induced liver injury in mice. Mice were given injections of V-PYRRO/NO (10 mg/kg, s.c. at 2-h intervals) before and after GlaN/LPS (700 mg/30 μg/kg, i.p.). V-PYRRO/NO administration dramatically reduced GlaN/LPS-induced hepatotoxicity, as evidenced by reduced serum alanine aminotransferase activity and improved pathology. To examine the mechanisms of the protection, cDNA microarray was performed to profile the gene expression pattern in livers of mice treated with GlaN/LPS, GlaN/LPS plus V-PYRRO/NO, or controls. V-PYRRO/NO administration greatly ameliorated GlaN/LPS-induced alterations in the expression of genes encoding the stress response, DNA damage/repair response, and drug-metabolizing enzymes in accordance with hepatoprotection. Gel shift assay and Western blot analysis supported microarray results, showing that V-PYRRO/NO suppressed GlaN/LPS-induced activation of nuclear factor-κB and GlaN/LPS-induced increases in caspase-1, caspase-8, tumor necrosis factor receptor 1 (TNFR1)-associated death domain, and TNF-related apoptosis-inducing ligand. Immunohistochemical analysis further revealed that GlaN/LPS-induced activation of TNFR1, caspase-3, and hepatocellular apoptosis was ameliorated by V-PYRRO/NO treatment. GlaN/LPS-induced elevation of hepatic caspase-3 activity was diminished by V-PYRRO/NO treatment. In addition, V-PYRRO/NO alone suppressed the basal expression of genes encoding inducible NO synthase and TNF-α-related components, as revealed by mouse 1.2 array. In summary, this study demonstrates that the liver-selective NO donor, V-PYRRO/NO, is effective in blocking GlaN/LPS-induced hepatotoxicity in mice, and that this protection appears to involve, at least in part, the suppression of the TNF-α-mediated cell death pathways.
Footnotes
-
This project has been funded in part by the National Cancer Institute/National Institutes of Health under Contract NO1-CO-56000.
- Abbreviations:
- V-PYRRO/NO
- O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate
- NO
- nitric oxide
- LPS
- lipopolysaccharide
- GlaN/LPS
- galactosamine plus LPS
- ALT
- alanine aminotransferase
- TNF-α
- tumor necrosis factor-α
- TNFR
- tumor necrosis factor receptor
- NF-κB
- nuclear factor-κB
- TRADD
- TNFR1-associated death domain
- TRAIL
- TNF-related apoptosis inducing ligand
- TBST
- Tris-buffered saline/Tween 20
- TUNEL
- terminal deoxynucleotidyl transferase dUTP nick-end labeling G3PDH, glyceraldehyde-3-phosphate dehydrogenase
-
- Received June 29, 2001.
- Accepted September 7, 2001.
- U.S. Government



